Lymph node-targeted metabolic regulatory nanovaccines to boost cancer immunotherapy by potentiating dendritic cell-mediated antigen presentation

experiments demonstrate that DAL inhibits tumorigenesis, attenuates tumor progression, and enhances the efficacy of immune checkpoint blockade (ICB) therapy. Collectively, this work provides a metabolic regulatory strategy for tumor vaccination, offering a potential approach to develop personalized vaccines for tumor immunotherapy.